Pharmacovigilance Training Online
Choose from 4 GPvP Online Courses

Pharmacovigilance 2 - Global Regulatory Requirements

Module 2 of 4 - Global Regulatory Requirements Course

If you would like to strengthen your pharmacovigilance knowledge then this course will help you comply with global regulatory requirements, which state that you must have a good understanding of the principles and guidelines within pharmacovigilance. The Pharmacovigilance Global Regulatory Requirements course is perfect for you if you are involved in all areas of drug safety, pharmacovigilance, regulatory and quality compliance and is a great addition to your knowledge in pharmacovigilance when combined with the Overview of Pharmacovigilance & Drug Safety course. Updated December 2019.

  • Average study time:
    study time

    3 hrs

  • Personal development points (CPD):

    3 points

  • Price:


Please enter the number of licences required.

Course Details

The Pharmacovigilance Global Regulatory Requirements course covers the key components of US and EU legislation, US and EU safety reporting regulations, including publications by the Council for International Organizations of Medical Sciences (CIOMS) and guidelines from the International Conference on Harmonisation (ICH).

The course delivers an explanation to the global regulatory requirements of pharmacovigilance and thoroughly explains the regulatory issues across global government agencies that improve safety across international markets. Keeping products on the market without interruption becomes more essential with the reduced pipeline of drugs in development. Successful navigation of drug safety and pharmacovigilance are keys to product longevity, consumer confidence and regulatory compliance. This module will provide you with a strong foundation of knowledge of the global legislation attributed with pharmacovigilance and drug safety.

Benefits for you

  • CPD Points - Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
  • Certification - Receive a personal certificate to show your subject knowledge on course completion.
  • Affordable - You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.
  • Flexibility - The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.
  • Keep Up to Date - You will stay up to date with any legislative changes in pharmacovigilance as our training courses are constantly monitored, reviewed and updated.
  • Learn from Industry Experts - The course content has been developed to ensure that you comply with pharmacovigilance legislation through the application of learning outcomes. The course is written by Steve Jolley, who is a chairperson for the Drug Information Association (DIA)

Course Syllabus

1. Learning Objectives for this Module

1.1 Learning Objectives

2. US Legislature

2.1 US Law

2.2 US Regulations

2.3 US Guidances

2.4 US Penalties for Non-Compliance

2.5 US Penalties for Non-Compliance II

3. EU Legislature

3.1 EU Legalities

3.2 EU Regulations

3.3 EU Directives

3.4 Why worry about EU PV laws?

3.5 Non-compliance subject to penalties in the EU

3.6 MHRA Infringement Notice

4. Matrix of Safety Regulations

4.1 Matrix of Safety Regulations

4.2 US Post-marketing Safety Reporting

4.3 FDA Regulation for IND safety reporting

4.4 IND Annual Report

4.5 Literature Reporting

4.6 International Conference on Harmonisation

4.7 ICH Topic Codes

4.8 Council of International Organizations of Medical Sciences (CIOMS)

4.9 Key EU Components

4.10 EU Member States

4.11 What is Europe?

5. EudraVigilance

5.1 Introduction

5.2 EudraVigilance – Pre-Marketing Requirements

5.3 EudraVigilance – Post-Marketing Requirements

5.4 EUDRA CT Database

6. The EU Clinical Trials Directive

6.1 EU Clinical Trial Guidance 2001/20/EC

6.2 Directive 2001/20/EC

6.3 Contents of EU Clinical Trials Directive

6.4 Supporting Guidance Documents

6.5 Intentions of Directive 2001/20/EC

6.6 Terminology in 2001/20/EC

6.7 Key Points

6.8 Key Points II

6.9 Volume 10

6.10 Volume 9A

6.12 QPPV

7. The Development Safety Update report (DSUR)

7.1 The Development Safety Update report (DSUR)

7.2 DSUR Format & Contents

8. Other European Regulations

8.1 Signalling

8.2 Good Pharmacovigilance Practice (GVP) & European Pharmacovigilance Legislation

8.3 European Pharmacovigilance Legislation - Quick Summary

8.4 Why the new EU PV laws were introduced

8.5 Pharmacovigilance Fees

8.6 GVP Modules

9. GVP Module I - Quality System

9.1 Requirements for Quality Systems

9.2 Audits

9.3 Inspections

10. GVP Module II - PV System Master File

10.1 Pharmacovigilance Systems Information

10.2 Content

11. GVP Module VI - ADR reporting

11.1 ADR Reporting

11.2 The Internet

11.3 Post-authorisation Studies

11.4 ICSR format

11.5 Biological products

12. GVP Module VII - Periodic Safety Update Report


12.2 PSUR Periodicity, ex-EU

12.3 PSUR Periodicity, EU

12.4 PSUR new features

12.5 PSUR Sections - Product status and patient exposure

12.6 PSUR Sections - Cumulative and Interval information

12.7 PSUR Sections - Analysis and Recommendations

13. GVP Module IX - Signal Management

13.1 Steps in the signal management process

13.2 Signal validation considerations

13.3 Signal Management - MAH responsibilities

13.4 EudraVigilance Monitoring

13.5 EudraVigilance Monitoring II


Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        Quintiles logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo                           
  • 21,183 STUDENTS
  • 9,400 COMPANIES